CN105130998A - 库潘尼西的制备方法 - Google Patents

库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130998A
CN105130998A CN201510618067.6A CN201510618067A CN105130998A CN 105130998 A CN105130998 A CN 105130998A CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 A CN105130998 A CN 105130998A
Authority
CN
China
Prior art keywords
pannixi
morpholine
reaction
base propoxy
methoxyl
Prior art date
Application number
CN201510618067.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130998B (zh
Inventor
许学农
王喆
包志坚
张文件
苏健
顾新禹
薛佳
袁玉环
Original Assignee
苏州立新制药有限公司
许学农
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州立新制药有限公司, 许学农 filed Critical 苏州立新制药有限公司
Priority to CN201510618067.6A priority Critical patent/CN105130998B/zh
Publication of CN105130998A publication Critical patent/CN105130998A/zh
Application granted granted Critical
Publication of CN105130998B publication Critical patent/CN105130998B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
CN201510618067.6A 2015-09-25 2015-09-25 库潘尼西的制备方法 CN105130998B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法
KR1020187011225A KR102104957B1 (ko) 2015-09-25 2016-07-01 코판리십의 제조방법
PCT/CN2016/088091 WO2017049983A1 (zh) 2015-09-25 2016-07-01 库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130998A true CN105130998A (zh) 2015-12-09
CN105130998B CN105130998B (zh) 2017-07-28

Family

ID=54716625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Country Status (3)

Country Link
KR (1) KR102104957B1 (und)
CN (1) CN105130998B (und)
WO (1) WO2017049983A1 (und)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5210558B2 (ja) 2007-07-12 2013-06-12 株式会社ブリヂストン 防振装置
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
KR20180096572A (ko) 2018-08-29
KR102104957B1 (ko) 2020-04-28
CN105130998B (zh) 2017-07-28
WO2017049983A1 (zh) 2017-03-30

Similar Documents

Publication Publication Date Title
US9303039B2 (en) Methods useful in the synthesis of halichondrin B analogs
ES2708224T3 (es) 4-Imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as inhibitors of Btk
CN108368113B (zh) 二氢吡啶并环化合物的晶型、制备方法和中间体
ES2672530T3 (es) Heterocyclic amides as kinase inhibitors
ES2551708T3 (es) Compuestos de 4-desdimetilamino tetraciclina
CN104130261B (zh) 艾德利布的合成方法
CN109311889A (zh) 激活素受体样激酶抑制剂
WO2016073767A1 (en) Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN104447739B (zh) 一种氘代Palbociclib衍生物、制备方法及应用
ES2730474T3 (es) Process for the preparation of ivacaftor and solvates of this
ES2793957T3 (es) Métodos de separación de diastereoisómeros de fosfato de gemcitabina
ES2441958T3 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4
KR20170026494A (ko) 치환된 뉴클레오타이드 유사체의 제조 방법
CA3050346A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
Reddy et al. 4β-[(4-Alkyl)-1, 2, 3-triazol-1-yl] podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation
CA2662626C (en) Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
CA2832685A1 (en) Pyrimidine derivatives for the treatment of viral infections
MX2015002090A (es) NEW BICYCLE DERIVATIVES.
CA2929661A1 (en) Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds
WO2017123884A1 (en) Heterocyclic compounds as rsv inhibitors
WO2010135520A1 (en) Compounds, compositions and methods for treating viral infection
CN101284827B (zh) 含三唑环萘酰亚胺抗肿瘤化合物及其制备方法
WO2010010347A1 (en) Pyrrolobenzodiazepines
CN104496983A (zh) 一种帕博西尼的制备方法
WO2011009898A1 (en) Fused aminodihydro-oxazine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200714

Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District

Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.

Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou

Co-patentee before: Xu Xuenong

Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.